Back to Search Start Over

A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution.

Authors :
Radin, Massimo
Schreiber, Karen
Cecchi, Irene
Bortoluzzi, Alessandra
Crisafulli, Francesca
Freitas, Cristiano M de
Bacco, Beatrice
Rubini, Elena
Foddai, Silvia G
Padovan, Melissa
Cassarino, Silvia Gallo
Franceschini, Franco
Andrade, Danieli
Benedetto, Chiara
Govoni, Marcello
Bertero, Tiziana
Marozio, Luca
Roccatello, Dario
Andreoli, Laura
Sciascia, Savino
Source :
Rheumatology. Sep2020, Vol. 59 Issue 9, p2412-2418. 7p.
Publication Year :
2020

Abstract

Objectives To investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD. Methods This multicentre retrospective cohort study describes the outcomes of 224 pregnancies in 133 consecutive women with a diagnosis of UCTD, positive for ANA and aged <45 years old at study inclusion. Results Of the 224 pregnancies analysed, 177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks' gestation), 2 (0.9%) in stillbirths (pregnancy loss after 20 weeks' gestation) and 6 (2.7%) cases showed intrauterine growth restriction. Miscarriages and stillbirths were strongly associated with the presence of aPL and ENA antibodies (P  < 0.05). Maternal pregnancy complications were as follows: 5 (2.2%) cases developed pre-eclampsia, 11 (4.9%) cases gestational hypertension and 12 (5.4%) cases gestational diabetes. Joint involvement represented the most frequent clinical manifestation of the cohort (57.9%), followed by RP (40.6%), photosensitivity (32.3%) and haematological manifestations (27.1%). The rate of disease evolution of our cohort from a diagnosis of UCTD to a diagnosis of definite CTD was 12% within a mean time of 5.3 ± 2.8 years. With a total follow-up after first pregnancy of 1417 patient-years, we observed the evolution to a defined CTD in one out of every 88 patient- years. Conclusion In our multicentre cohort, women with UCTD had a live birth rate of 79%. Women with UCTD should be referred to specialist follow-up when planning a pregnancy. ENA profiling and aPL testing should be mandatory in this setting, and further therapeutic approaches and management should be planned accordingly. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14620324
Volume :
59
Issue :
9
Database :
Academic Search Index
Journal :
Rheumatology
Publication Type :
Academic Journal
Accession number :
145386517
Full Text :
https://doi.org/10.1093/rheumatology/kez620